Basic Science in Movement Disorders: Fueling the Engine of Translation into Clinical Practice.
Parkinson's disease
basic science
movement disorders
translational research
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
04 Apr 2024
04 Apr 2024
Historique:
revised:
11
03
2024
received:
21
02
2024
accepted:
15
03
2024
medline:
5
4
2024
pubmed:
5
4
2024
entrez:
5
4
2024
Statut:
aheadofprint
Résumé
Basic Science is crucial for the advancement of clinical care for Movement Disorders. Here, we provide brief updates on how basic science is important for understanding disease mechanisms, disease prevention, disease diagnosis, development of novel therapies and to establish the basis for personalized medicine. We conclude the viewpoint by a call to action to further improve interactions between clinician and basic scientists. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : European Research Council
ID : 951294
Pays : International
Informations de copyright
© 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Références
Lees AJ, Tolosa E, Olanow CW. Four pioneers of L‐dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. Mov Disord 2015;30(1):19–36. https://doi.org/10.1002/mds.26120
Carlsson A, Lindqvist M, Magnusson T. 3,4‐Dihydroxyphenylalanine and 5‐hydroxytryptophan as reserpine antagonists. Nature 1957;180(4596):1200.
Olanow CW, Obeso J. Profile of Mahlon DeLong and Alim Benabid, 2014 Lasker‐DeBakey medical research awardees. Proc Natl Acad Sci U S A 2014;111(50):17693–17695.
Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine‐analog synthesis. Science 1983;219(4587):979–980. https://doi.org/10.1126/science.6823561
Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine. Proc Natl Acad Sci U S A 1983;80(14):4546–4550. https://doi.org/10.1073/pnas.80.14.4546
Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990; 249(4975):1436–1438. https://doi.org/10.1126/science.2402638
Cardoso F. Botulinum toxin in parkinsonism: the when, how, and which for botulinum toxin injections. Toxicon 2018;147:107–110.
Basic Science SIG. International Parkinson and Movement Disorder Society; Accessed February 8, 2024. https://www.movementdisorders.org/MDS/About/Groups/Special-Interest-Groups/Basic-Science.htm.
Outeiro TF, Heutink P, Bezard E, Cenci AM. From iPS cells to rodents and nonhuman primates: filling gaps in modeling Parkinson's disease. Mov Disord 2021;36(4):832–841.
Schumacher‐Schuh AF, Bieger A, Okunoye O, et al. Underrepresented populations in Parkinson's genetics research: current landscape and future directions. Mov Disord 2022;37(8):1593–1604.
Tian W, Zhou J, Bartlett A, et al. Single‐cell DNA methylation and 3D genome architecture in the human brain. Science 2023;382(6667):eadf5357.
Bose A, Petsko GA, Studer L. Induced pluripotent stem cells: a tool for modeling Parkinson's disease. Trends Neurosci 2022;45(8):608–620.
Outeiro TF, Vieira TCRG. AI and protein structure and function in neurological disease: relevance to disease management. Nat Rev Neurol 2023;19(8):453–454.
Duan W, Urani E, Mattson MP. The potential of gene editing for Huntington's disease. Trends Neurosci 2023;46(5):365–376.
Jennings D, Huntwork‐Rodriguez S, Henry AG, et al. Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease. Sci Transl Med 2022;14(648):eabj2658.
Zimprich A. LRRK2 PROTAC degraders as a potential novel targeting strategy for Parkinson's disease? Mov Disord 2022;37(11):2193.
Tosefsky KN, Zhu J, Wang YN, Lam JST, Cammalleri A, Appel‐Cresswell S. The role of diet in Parkinson's disease. J Parkinsons Dis 2024:1–14. https://doi.org/10.3233/JPD-230264. Epub ahead of print.
Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha‐synuclein gene identified in families with Parkinson's disease. Science 1997;276(5321):2045–2047. https://doi.org/10.1126/science.276.5321.2045
Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha‐synuclein in Lewy bodies. Nature 1997;388(6645):839–840. https://doi.org/10.1038/42166
Siderowf A, Concha‐Marambio L, Lafontant DE, et al. Assessment of heterogeneity among participants in the Parkinson's progression markers initiative cohort using α‐synuclein seed amplification: a cross‐sectional study. Lancet Neurol 2023;22(5):407–417.
Höglinger GU, Adler CH, Berg D, et al. A biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria. Lancet Neurol 2024;23(2):191–204.
Simuni T, Chahine LM, Poston K, et al. A biological definition of neuronal α‐synuclein disease: towards an integrated staging system for research. Lancet Neurol 2024;23(2):178–190.
Paul KC, Krolewski RC, Lucumi Moreno E, et al. A pesticide and iPSC dopaminergic neuron screen identifies and classifies Parkinson‐relevant pesticides. Nat Commun 2023;14(1):2803.
Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha‐synuclein linked to early‐onset Parkinson disease. Nat Med 1998;4(11):1318–1320.
Prusiner SB. Prions. Proc Natl Acad Sci U S A 1998;95(23):13363–13383. https://doi.org/10.1073/pnas.95.23.13363
Caughey B, Baron GS. Prions and their partners in crime. Nature 2006;443(7113):803–810. https://doi.org/10.1038/nature05294
Okuzumi A, Hatano T, Matsumoto G, et al. Propagative α‐synuclein seeds as serum biomarkers for synucleinopathies. Nat Med 2023;29(6):1448–1455.
Cardoso F, Goetz CG, Mestre TA, et al. A statement of the MDS on biological definition, staging, and classification of Parkinson's disease. Mov Disord 2024;39(2):259–266. https://doi.org/10.1002/mds.29683
Mitchell T, Lehéricy S, Chiu SY, Strafella AP, Stoessl AJ, Vaillancourt DE. Emerging neuroimaging biomarkers across disease stage in Parkinson disease: a review. JAMA Neurol 2021;78(10):1262–1272.
Bednarik P, Goranovic D, Svatkova A, et al. 1H magnetic resonance spectroscopic imaging of deuterated glucose and of neurotransmitter metabolism at 7 T in the human brain. Nat Biomed Eng 2023;7(8):1001–1013.
Matsuoka K, Ono M, Takado Y, et al. High‐contrast imaging of α‐synuclein pathologies in living patients with multiple system atrophy. Mov Disord 2022;37(10):2159–2161.
Smith R, Capotosti F, Schain M, et al. The α‐synuclein PET tracer [18F] ACI‐12589 distinguishes multiple system atrophy from other neurodegenerative diseases. Nat Commun 2023;14(1):6750.
Chen R, Berardelli A, Bhattacharya A, et al. Clinical neurophysiology of Parkinson's disease and parkinsonism. Clin Neurophysiol Pract 2022;7:201–227.
Braz BY, Wennagel D, Ratié L, et al. Treating early postnatal circuit defect delays Huntington's disease onset and pathology in mice. Science 2022;377(6613):eabq5011.
Bennett CF, Kordasiewicz HB, Cleveland DW. Antisense drugs make sense for neurological diseases. Annu Rev Pharmacol Toxicol 2021;61:831–852.
Pagano G, Taylor KI, Anzures‐Cabrera J, et al. Trial of prasinezumab in early‐stage Parkinson's disease. N Engl J Med 2022;387(5):421–432.
Lang AE, Siderowf AD, Macklin EA, et al. Trial of cinpanemab in early Parkinson's disease. N Engl J Med 2022;387(5):408–420.
Outeiro TF, Alcalay RN, Antonini A, et al. Defining the riddle in order to solve it: there is more than one “Parkinson's disease”. Mov Disord 2023;38(7):1127–1142.